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Abstract. One of the characteristic pathological hallmarks of Alzheimer’s disease (AD) is neuritic plaques. The sequence of
events leading to deposition of amyloid- (A) peptides in plaques is not clear. Here we investigate the effects of D3, an A
oligomer directed D-enantiomeric peptide that was obtained from a mirror image phage display selection against monomeric
or small oligomeric forms of A42, on A deposition in aged APP/PS1 double transgenic AD-model mice. Using Alzet
minipumps, we infused the brains of these AD model mice for 8 weeks with FITC-labeled D3, and examined the subsequent
changes in pathology and cognitive deficits. Initial cognitive deficits are similar comparing control and D3-FITC-treated mice,
but the treated mice show a significant improvement on the last day of testing. Further, we show that there is a substantial
reduction in the amount of amyloid deposits in the animals treated with D3-FITC, compared to the control mice. Finally, the
amount of activated microglia and astrocytes surrounding A deposits is dramatically reduced in the D3-FITC-treated mice.
Our findings demonstrate that treatments with the high affinity A42 oligomer binding D-enantiomeric peptide D3 significantly
decrease A deposits and the associated inflammatory response, and improve cognition even when applied only at late stages
and high age. Together, this suggests that the treatment reduces the level of A peptide in the brains of APP/PS1 mice, possibly
by increasing A outflow from the brain. In conclusion, treatments with this D-peptide have great potential to be successful in
AD patients.
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INTRODUCTION
Alzheimer’s disease (AD), a progressive neurode-
generative disorder, is associated with several risk
factors, including age and inheritance, i.e., genes and
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sity Blvd. THT 912, Birmingham, AL 35294, USA. Tel.: +1 205
9345940; E-mail: vangroen@uab.edu.
epigenetics. The majority of AD cases are late onset,
lack an obvious genetic etiology, and are characterized
as sporadic, whereas only a very small percentage of
the cases are early in onset and segregates strongly
within families. Most of the early-onset cases of
AD are inherited as autosomal dominant disorders
caused by mutations in either the presenilin 1 (PS1)
gene on chromosome 14, the presenilin 2 (PS2) gene
on chromosome 1, or the amyloid- protein precur-
sor (APP) gene on chromosome 21 (e.g., [1]). The
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pathology of AD is characterized by extracellu-
lar amyloid- (A) peptide containing plaques,
and intracellular neurofibrillary tangles consisting of
aggregated, hyperphosphorylated tau protein [2].
Plaques are primarily made up of A42 [3, 4]. A is
a 39–43 amino acid [5] peptide derived from the pro-
teolytic processing of the APP (e.g., [5, 6]). When
APP is sequentially cleaved by the -secretase and
the -secretase, the resulting cleavage product is A;
in contrast, cleavage by -secretase does not lead to
A production [6]. Most mutations in APP and PS1
(and PS2) alter APP metabolism such that there is
an increased production of A (especially the longer,
fibrillogenic A42 [1, 6, 7]). Furthermore, it has been
shown that duplication of the APP gene leads to early
onset AD [8–10]. Finally, it has also been shown that
variations in the promoter region of the APP gene
affect the risk of AD [11]. Together this implies a cen-
tral role for aberrant APP processing in the series of
pathological changes occurring during AD, character-
ized by the appearance of the typical neuritic plaques
of AD.
Transgenic (Tg) mice expressing mutated human
AD genes offer a powerful model to study the role of
A in the development of AD pathology (e.g., [12]).
The present study employs Tg mice expressing both
the human APPswe and PS1E9 mutations [13].
These mice develop elevated levels of A42 at about
four months of age, and around 5 months of age, they
show A plaques [13, 14]. Furthermore, it has been
shown that these mice develop cognitive deficits at
the age that A pathology appears, i.e., at 6 months
of age, with increasing memory deficits at later ages
[15, 16].
Most likely, amyloid deposition in the brain is
caused by an imbalance between A production and
A clearance. Even a small imbalance will lead, over
the years, to a significantly increased A load in the
brain, especially in animals that have a long lifespan
and humans. Several mechanisms have been pro-
posed for the clearance of A, receptor-mediated A
transport across the blood-brain barrier and enzyme-
mediated degradation of the peptide [17, 18]. A
possible therapeutic invention that has been proposed is
interference in the accumulation and deposition of the
A protein in aggregates [19, 20]. We have developed a
series of D-enantiomeric peptides, using mirror-image
phage display techniques, that bind A, with a pref-
erence for A42 [21–26]. We have demonstrated that
the small D-enantiomeric peptide D3 (D3-FITC) that
specifically precipitates oligomers in a mixture con-
taining monomers and oligomers of A42 [27] reduces
amyloid deposition and decrease cognitive deficits in
young Tg AD model mice when they are infused intrac-
erebrally or treated by oral administration [26, 28, 29].
In this study we used Alzet minipumps to infuse the
hippocampus of old Tg AD model mice for 8 weeks
with the FITC-labeled version of D3. We examined
cognitive deficits in the last two weeks of treatment,
and A deposits in hippocampus and cortex following
sacrifice after the final behavioral testing (i.e., at the
end of the eighth week of treatment). The data demon-
strate that infusion with the D3-FITC peptide leads to
a reduction in the size and number of A deposits in
the hippocampus (and nearby neocortex), whereas the
infusion with the vehicle solution does not change A
deposits. Similarly, the amount of inflammation (i.e.,
activated astrocytes and microglia) was significantly
reduced in the D3-FITC treated mice. The eight week
infusion of the peptide also leads to a small, but signif-
icant, improvement in one cognitive measure in these
old Tg AD model mice.
MATERIALS AND METHODS
Animals
Old male APP and PS1 double Tg mice
(APPswe/PS1E9 mice, n = 11) [13] were used in
the present study. The mice were a kind gift of
Dr. S. Handattu; until the treatments, the animals
were housed 4/cage in our facility, in a controlled
environment (temperature 22◦C, humidity 50–60%,
light from 07 : 00–19 : 00), food and water were avail-
able ad libitum. Following the implantation of the
Alzet minipump, the animals were housed individu-
ally. The experiments were conducted according with
the local Institutional Animal Care and Use Committee
(IACUC) guidelines.
Peptides
The identification of D3 is described elsewhere
[24–27]. We chose to use D3-FITC (i.e., D3 conju-
gated with a FITC moiety via an additional C-terminal
lysine; D3 sequence: rprtrlhthrnr) because we wanted
to follow its fate in the animal and the FITC-label does,
if at all, positively affect the D3 A binding properties
[30].
Hippocampal infusion
In two groups of twenty-one months old mice, we
unilaterally infused the hippocampus for eight weeks
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using Alzet osmotic minipumps, one group (control
group; n = 5) with saline, one group with the D3-FITC
dissolved in saline (D3-FITC group; n = 6). The pep-
tide concentration was 0.25 mg/pump, i.e., 0.25 mg in
250l. The Alzet minipump (model #2004; delivery
rate: 0.25l/h; duration 4 weeks: Alzet) was soaked
in sterile saline for 24 h prior to implantation; the
next day the pump, the connecting tube, and cannula
(Alzet Brain Infusion Kit 3; Alzet) were filled with the
appropriate solution, and were connected, such that
no air bubbles were present. Finally, the cannula were
implanted in the brain (right dorsal hippocampus);
in short, mice were anesthetized, placed in a stereo-
taxic frame, a hole was drilled above the right dorsal
hippocampus, and the cannula was lowered into the
hippocampus (coordinates: A-2, L-1.5, V-2.2; [31]).
After four weeks the pumps were replaced by new
pumps filled with the appropriate solution. Six and a
half weeks after the start of the infusion the animals
were tested in the water maze; seven and a half weeks
after the implantations the animals were tested in the
Barnes maze, and then sacrificed for histopathological
analysis (see below).
Behavior
The animals were tested for one week in an open
field water maze. Our version of the maze consists of a
blue circular tank of clear water (23 ± 1◦C). The mice
are placed in the water at the edge of the pool and
allowed to swim in order to locate a hidden, but fixed
escape platform, using extramaze cues. On day 1, the
mice are placed in the pool and allowed to swim freely
for 90 s to find the hidden platform (or until they find
the hidden platform); each animal is tested for four
trials per day. A maximum swim time per trial of 90 s
is allowed; if the animal does not locate the platform
in that time, it is placed upon it by the experimenter
and left there for 10 s. The inter-trial interval is 120 s.
Each start position (east, north, south, and west) is
used equally in a pseudo random order and the animals
are always placed in the water facing the wall. All four
possible quadrant positions for the platform locations
are equally used among all of the animals. The platform
is placed in the middle of one of the quadrants of the
pool (i.e., northwest, southwest, northeast, or south-
east; approximately 30 cm from the side of the pool).
The mouse’s task throughout the experiment is to find,
and escape on to, the platform. Once the mouse has
learned the task (day 5, trial 20), a probe trial is given
immediately following the last trial of acquisition on
day 5. In the probe trial (i.e., trial 21), the platform
is removed from the pool and animals are allowed to
swim for 60 s.
The Barnes maze that is used has a design simi-
lar to the one developed by Barnes et al. [32] for rats
and that has been adapted to the mouse. The raised
(120 cm above the floor), round platform has a diam-
eter of 140 cm, the escape holes are distributed along
the rim of the platform (Columbus Instruments), and
the maze is positioned in a brightly lit room. Only one
of them, the correct escape hole, has the escape cage
attached under it. The mice are trained to escape from
the open platform (the start position is in the middle of
the platform) to the escape cage. An entry into an incor-
rect hole is deemed a reference memory error, and an
entry into a hole where it was before is a working mem-
ory error. The mice are removed from the maze after
escaping or after 4 min has passed, whichever comes
first. An entry is defined as the head entering the escape
hole. Learning of the task is evaluated by recording the
latency to find the correct escape hole, the path length,
and percentage of trials each animal finds the correct
hole. Four trials are run per day; the learning of the
maze takes an average of 5 days. After each testing
day, the apparatus is wiped down with chlorhexidine
and 70% ethanol and allowed to air-dry.
Histopathology
In short, mice were anesthetized and transcardially
perfused. Then the brains were removed and cut in
half, and the right hemisphere was dropped in 4%
paraformaldehyde. The left hemisphere was divided
into four parts (rostral and caudal cortex, hippocam-
pus, and non-cortex) and frozen and stored at –80◦C
for western and ELISA analysis. Following postfix-
ation (overnight in the fixative) and cryoprotection
(30% sucrose for 24 h followed by antifreeze [15%
sucrose and 30% ethylene glycol in 0.05 M phosphate
buffer, pH 7.4), six series (1 in 6) of coronal sections
were cut through the brain. The first series of sec-
tions was mounted unstained; the second and third
series were stained immunohistochemically accord-
ing to published protocols [14]; and the other three
series were stored in at –20◦C in antifreeze for future
analysis. One half of the second series was stained
for human A using the W0-2 antibody (mouse anti-
human A4-9; 1 : 5000; [33]), while the other half of
the second series was stained for mouse A (rabbit
anti-rodent A;1 : 5000; Covance) [14]. One half of the
third series was stained for GFAP (mouse anti-GFAP;
1 : 1000; Sigma), whereas the other half was stained for
CD11b (rat anti-mouse CD11b; 1 : 10000; Serotec), a
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marker of microglia. Some of these stained sections
were double stained with either Congo red, thioflavine
S, or thiazine red. A few sections were stained for
cathepsin D (goat anti-cathepsin D; 1 : 1000; Santa
Cruz), a marker of lysosomes. The sections destined
for A staining were pretreated for 30 min with hot
(85◦C) citrate buffer. The series of sections were trans-
ferred to a solution containing the primary antibody;
this solution consists of TBS with 0.5% Triton X-100
added (TBS-T). Following incubation in this solution
for 18 h on a shaker table at room temperature (20◦C) in
the dark, the sections were rinsed three times in TBS-T
and transferred to the solution containing the secondary
antibody (goat anti-mouse*biotin, Sigma or sheep anti-
rat Ig*biotin, Serotec). After 2 h, the sections were
rinsed three times with TBS-T and transferred to
a solution containing mouse ExtrAvidin peroxidase
(Sigma), following rinsing the sections were incu-
bated for approximately 3 min with Ni-enhanced DAB
[34]. In a small number of sections, the A deposits
were double labeled for A40, A42, GFAP, or CD11b
using fluorescent secondary antibodies. All stained and
unstained sections (of series 1–3) were mounted on
slides and coverslipped.
ELISA
In short, diluted brain samples (i.e., the hippocam-
pus) were assayed for A in triplicate using the Beta-
Mark x-40 and BetaMark x-42 ELISA kits (Covance),
according to the manufacturer’s protocol. For the mea-
surement of soluble and insoluble A, the mouse brain
tissue (the hippocampus) was prepared according to
our modification of the manufacturer’s protocol [35].
Briefly, the brain tissues were homogenized in an
A extraction buffer containing 20 mM Tris-HCl (pH
7.6), 137 mM NaCl, 1% Triton X-100, 2% SDS, and
protease inhibitors (complete protease inhibitor cock-
tail, Boehringer Mannheim, Mannheim, Germany),
and centrifuged at 100,000 g for 1 h. Supernatant was
collected (SDS soluble) and stored at –80◦C until anal-
ysis or analyzed immediately. Pellets were dissolved
in 70% formic acid (FA), incubated at room tempera-
ture with gentle shaking for 2 h, and then centrifuged
at 100,000 g for 1 h. The supernatants were collected
(SDS insoluble). The FA extraction solution was neu-
tralized and diluted 20 times with a neutralizing buffer
containing 1 M Tris, 0.5 M Na2HPO4, and 0.05%
NaN3 before analysis by ELISA. In vivo administered
D3 was confirmed not to interfere with the ELISA kit
for the analyses of A in the samples from this study
(the caudal brain samples were used for this analysis).
Quantification
The appropriate areas (dorsal hippocampus and mid-
line dorsal and frontal cortices) of the brain were
digitized using a Olympus DP70 digital camera [34].
To avoid changes in lighting, which might affect mea-
surements, all images were acquired in one session
with a fixed setting for the light level. Further, to avoid
differences in staining density between sections, the
measurements were performed on sections that were
stained simultaneously, i.e., in the same staining tray.
The percentage of area covered by the reaction prod-
uct to A was measured in the hippocampus (and
frontal cortex) using the ScionImage (NIH) program
[34, 35]. The threshold for the measurements was set
at the appropriate level to avoid measuring background
staining, and used for all images. Using a similar pro-
cedure, using digital images able to overlay the defined
measurement area, plaques were counted in the same
brain area on the adjacent sections that were stained
with Congo red. The density of GFAP or CD11b stain-
ing was measured by placing a standard sized circle
(200m diameter) around the plaque core (stained
with Congo red), and measuring the optical density of
the staining in the circle using the ScionImage (NIH)
program. All density measurements were done in trip-
licate, i.e., measuring the standardized area around
three plaques at three different levels of the dorsal hip-
pocampus and the frontal, midline cortex. These mea-
surements were done in triplicate in sections (that had
been stained simultaneously) by an observer blinded
to the treatment of the animal. All data were analyzed
by ANOVA (Systat 11; between groups), and post-hoc
tests (Tukey and Scheffe) were carried out to determine
the source of a significant main effect or interaction.
All data are shown with as the average ± SEM.
RESULTS
The implantation of the Alzet minipumps and brain
cannulas did not change any obvious physiological
parameters (e.g., body weight or general health, i.e.,
the look of fur, posture, and motor activity) in the
implanted mice, or cause any noticeable discomfort.
None of the animals lost the brain cannula or devel-
oped any health or motor problems. One animal turned
out to be negative for human APP expression and A
deposits, most likely because it had been incorrectly
genotyped.
After six and a half weeks of infusion, the two groups
(i.e., control and D3-FITC treated) of APP/PS1 mice
were tested in the water maze. There was no significant
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Fig. 1. Three graphs showing the learning curves of the three groups of mice: A) the daily mean performance in the water maze; B) the probe
trial performance of the two groups of mice (L = left, C = correct, A = across, and R = right quadrant); C) the daily mean performance in the
Barnes maze; and D) examples of tracks of a control and a D3-FITC mouse in the Barnes maze. *indicates significantly (p < 0.05) different on
last day of testing.
difference in the swimming speed between the groups
of mice (14.9 ± 2.4 m/s and 15.3 ± 2.4 cm/s, respec-
tively). At the end of the week of training, there was
no difference in escape latency between the two groups
of mice in water maze performance (Fig. 1A); fur-
thermore, neither of the two groups of mice showed
any significant improvement of learning during the
week of testing. Moreover, as expected, none of the
groups showed a preference for the correct quadrant
in the probe trial which followed the last training trial
(Fig. 1B). The week following the water maze test,
the animals were trained on the Barnes maze. At the
end of the week of training, there was a small, but sig-
nificant, difference in escape latency between the two
groups of mice (Fig. 1C), with the D3-FITC group of
mice showing a significant improvement of learning
at the last day of testing. There was also a signifi-
cant difference in the number of correct responses on
that day, 14/20 (D3-FITC) versus 2/20 (control). There
was no significant difference in the average distance
the animals moved (212 ± 35 cm and 193 ± 34 cm,
D3-FITC and control, respectively; Fig. 1), but the
D3-FITC treated mice had a slightly but not signifi-
cantly faster average speed of moving (1.2 ± 0.3 versus
0.9 ± 0.4 cm/s). It should be noted that the difference
in average speed was caused by longer periods of non-
moving in the control mice (corrected average speeds:
1.3 ± 0.3 and 1.2 ± 0.4 cm/s, respectively). Similarly,
for both groups, the walking speed in the Barnes maze
is much slower than the swimming speed in the water
maze. After completion of the behavioral testing, the
animals were sacrificed and the brains were assessed
for A levels, A load, and AD pathology-related
inflammation.
The implantation of the cannula was in the dor-
sal hippocampus in all animals (Fig. 2). The extent
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Fig. 2. Two sets of three photomicrographs (A–F) of coronal sec-
tions through the dorsal midline cortex and hippocampus of the two
groups of APP/PS1 mice and three high power photmicrographs
(G–I). Top row (A, B) unstained sections, lower two rows, sections
stained for A (with W0-2), middle row (C, D) hippocampus, and
bottom row (E, F) rostral midline cortex. Three high power photomi-
crographs: G) parietal cortex showing D3-FITC labeled perivascular
macrophages (red arrow); H) labeled microglia cells in area CA1;
and I) labeled neurons in the dentate gyrus. Please note the differ-
ence in A staining density in the hippocampus between the treated
and non-treated mice.
of the distribution of the infused peptide in the brain
could be analyzed in the unstained sections of the brain
since the infused D-peptide was conjugated to a FITC
molecule. Inspection of brain sections with an epifluo-
rescent microscope revealed that all dense A deposits
in the whole brain were FITC-labeled, with a decrease
in brightness further from the infusion site (Fig. 3).
It should be noted that all plaques, i.e., A deposits
with a Congo red positive core and some A deposits
in blood vessel walls were labeled, but diffuse A
deposits were not labeled by the D3-FITC peptide. As
expected, none of the control infused mice showed any
D3-FITC-labeled A deposits (Fig. 2A).
A B
C D
50 µm
Fig. 3. Four high power photomicrographs (A–D) of coronal sec-
tions through the dorsal, midline cortex following long-term infusion
of D3-FITC: A) image of labeled plaques >3 mm away from the infu-
sion site; B) image of labeled plaques ∼1 mm from the infusion site;
C) image showing labeled plaques near the infusion site; and D)
labeled plaques at the injection site. Notice the increase in staining
density in plaques near the infusion site. Red arrows in C indicate
dystrophic neurites.
It is notable that near the infusion site, but not else-
where in the brain, many neurons showed signs of
having taken up D3-FITC, i.e., they showed intracel-
lular FITC labeling (Fig. 2H, I). Most of the D3-FITC
labeling is present on the A42 surrounding the dense
core of A plaques (Fig. 3), but some labeling is
present in the dystrophic axons surrounding the plaque
(Fig. 3). Furthermore, in the D3-FITC infused mice
a small number of layer II neurons in the entorhi-
nal cortex (and a few cells in the cholinergic basal
forebrain; not illustrated) showed intracellular label-
ing with D3-FITC, likely due to D3-FITC that was
retrogradely transported from the infusion site, i.e., the
dorsal hippocampus (not illustrated). It is of interest to
note that these neurons showed D3-FITC labeling in
lysosomes (confirmed with double labeling with lyso-
somal marker, cathepsin D). Further, some perivascular
macrophages throughout the brain showed labeling
with D3-FITC (Figs. 2G and 5A), and it should be
noted that these were mainly present on penetrating
arterioles. Finally, the D3-FITC peptide had also been
taken up by a few microglial cells (Figs. 2H and 5D),
and these microglial cells were mainly present sur-
rounding A deposits near the infusion site, but a
few microglial cells near the infusion site also showed
intracellular labeling with D3-FITC (Fig. 5D). Double-
labeling with GFAP demonstrated that no D3-FITC
labeled astrocytes were present anywhere in the brain
(not illustrated).
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Table 1
The number of animals per group, body weight, the A load, the
number of Congo Red positive plaques, and the density of GFAP and
CD11b staining around plaques in the dorsal hippocampus, numbers
are average ± SEM
Group Control D3-FITC
Infusion Saline D3-FITC peptide
Number n = 5 n = 5
Body weight 36.1 ± 2.5 g 37.2 ± 2.8 g
A load - hip 5.0 ± 0.4% 1.8 ± 0.3%*
A load - cort 9.8 ± 0.9% 9.0 ± 1.0%
A40 insoluble 201246 ± 36166 pg/g 68264 ± 1993 pg/g*
A40 soluble 11686 ± 1824 pg/g 7403 ± 499 pg/g*
A42 insoluble 495730 ± 15767 pg/g 355922 ± 9258 pg/g*
A42 soluble 174109 ± 2182 pg/g 10416 ± 2437 pg/g*
Congo Red # 157 ± 17 73 ± 9*
GFAP 102 ± 2 82 ± 2*
CD11b 159 ± 3 135 ± 3*
*indicates significantly different between control and D3-FITC
treated, p < 0.05.
In the sections that were stained for human A4-10,
the A load was measured in the hippocampus and
dorsal, midline cortex and frontal cortex. In the group
infused with D3-FITC there was significant reduction
in the A load in the hippocampus and in the dorsal
midline cortex, compared to the control-infused mice
(Figs. 2C, D; Table 1). In contrast, there was no dif-
ference in the A load between the control and the
D3-FITC infused mice in brain areas more than 3 mm
away from the infusion site, i.e., in the frontal cor-
tex (Figs. 2E, F; Table 1). The analysis of labeling for
mouse A showed a small but significant decrease in
mouse A load in the hippocampus in the D3-FITC
group compared to the control group.
The A levels were measured in the contralateral
(non-infused) hippocampus, and both the levels of the
soluble and insoluble A40 and A42 were signifi-
cantly reduced in the D3-FITC treated mice compared
to the untreated control mice (Fig. 4).
Analysis of the sections that were stained for
GFAP or microglia revealed that the implantation
of the cannula and the infusions did not cause any
significant inflammation (Fig. 6). The only infusion-
related inflammation that was present was around the
implanted infusion cannula (not illustrated), and was
similar among the two groups of mice. A more detailed
analysis of the magnitude of inflammation surround-
ing A deposits, however, revealed that the D3-FITC
treatment significantly reduced the amount of plaque-
related inflammation (measured in both GFAP and
CD11b staining) compared to the control brains in the
brain area near the infusion site (Fig. 6, Table 1). Dou-
ble staining for microglia and GFAP confirmed that at
D3-FITC labeled plaques both glial cell types were sig-
nificantly less activated compared to control-infused
mice.
DISCUSSION
In this study we infused the hippocampus of Tg
AD model mice for eight weeks with the small
D-enantiomeric peptide D3 conjugated to FITC (D3-
FITC) that has a high affinity for oligomeric A42 [23,
24, 26], and examined cognitive performance after 6.5
weeks, and the A load after the end of the cognitive
testing.
One of the two characteristic pathological hallmarks
of AD is the presence of neuritic plaques [36]. These
plaques have a dense core of aggregated A peptides
(e.g., [3]), which stains with thioflavine-S and Congo
red. However, diffuse amyloid deposits have also been
shown to be present in AD brains, and they have been
shown to be present in AD model mice [14]. In our
experiments, all dense plaques were labeled by D3-
FITC; in contrast, diffuse deposits, i.e., A deposits
200000 600000
480000
360000
240000
120000
0
160000
120000
80000
40000
0
ins
ins
sol
sol
ins
ins
sol
sol
control controlD3-FITC D3-FITC
Aβ
 
42
 n
g/
g
Aβ
 
40
 n
g/
g
*
*
*
*
Fig. 4. Two graphs showing the A40 and A42 levels in the hippocampus. Please note the significant (*; p < 0.05) decrease in both the insoluble
and soluble A40 and A42 levels in the treated mice compared to the control mice.
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Fig. 5. High power photomicrographs demonstrating plaques in
double-labeled coronal sections of the midline cortex, of mice that
were control or D3-FITC infused. Top four images, GFAP (i.e.,
GFAP and Congo red); bottom four images, microglia (i.e., Iba-1
and A or D3-FITC). Left column control-infused mice, and right
column D3-FITC-infused mice. Please note the reduction in the level
of inflammation between the two treatments.
without a thioflavine-S positive core, did not show any
labeling with the peptide. The diffuse deposits did not
show much, if any, labeling with A42 specific anti-
bodies [14], which is likely why the D3-FITC did not
bind to these deposits. In contrast, some A in blood
vessel walls (cerebral amyloid angiopathy) is labeled
by D3-FITC. Similarly, D3 did not bind A deposits in
blood vessel walls in young mice when they predomi-
nantly consist of A40 [37], but it should be noted that
at the ages when A42 is present in these deposits the
D3-FITC does label them [28], as D3-FITC also does
in these old mice. In agreement with these findings, in
earlier in vitro experiments, we have shown that at high
ages (>15 months of age) these deposits are labeled by
A42 antibodies and with both D1 and D3 [30].
The data from our experiments show that the D3-
FITC infused mice have a much lower A load in the
hippocampus, demonstrating that binding of D3-FITC
to oligomeric A42 helps in reducing A deposition
in the hippocampus and the adjacent neocortex. How-
ever, not only is amyloid deposition decreased, existing
deposits are also significantly cleared as the typical
plaque load of mice at the age, when the treatment
started (21 months) is much higher than observed
after D3-FITC treatment. This, most likely, is partially
brought about by changes in the aggregation properties
of the A42-D3-FITC complex, compared to the high
propensity of A42 to aggregate [38, 39]. This would
then lead to a decrease in the A deposition rate, and
thus a lesser number and/or smaller plaques [27]. Sev-
eral studies have shown that the use of-sheet breakers
[40–42] can reduce A aggregation and Adeposition,
both in vitro and in vivo. Our data confirm that even
treatment with an A42 binding peptide alone (i.e.,
without attached -sheet breaker) will decrease amy-
loid deposition. Insoluble A1-40 is even more reduced
after D3-FITC treatment than insoluble A1-42, most
probably because insoluble A aggregates consist of
mixtures of A1-40 and A1-42 and the higher the
A1-40 content is, the less stable the aggregates are
and the more amenable they are to D3-FITC, even if
D3 was reported to bind preferentially A1-42. On the
other hand, it is also possible that the clearance of the
D3-A42 complex from the brain has improved com-
pared to the clearance of A42 [18, 43, 44]. Several
mechanisms have been proposed for the clearance of
A, receptor-mediated A transport across the blood-
brain barrier and enzyme-mediated degradation of the
peptide [18, 43]. It is more likely that A transport
out of the brain is improved than that A degradation
has increased, since the properties of the A42-D3-
FITC complex are possibly not improving enzymatic
degradation [45].
All plaques in our AD-model mice are accompanied
by activated glial cells, both astrocytes and microglia
(e.g., [46–48]). The role of the activated glial cells is
unclear: on the one hand they could protect the brain
by removing A, on the other hand they can secrete
inflammatory cytokines and generate nitric oxide, and
can thus damage and kill bystander neurons [49]. It
should be noted that in this mouse model, no dead or
dying neurons are present, even near plaques [47]. The
role of activated microglia cells in the uptake of A
is disputed, with some groups showing clearance of
A by microglia (e.g., [50, 51], whereas others have
shown that microglia do not take up A [52]. Simi-
larly, the plaques in all our animals are surrounded by
activated glial cells; however, in the D3-FITC infused
mice, only microglial cells show fluorescence intracel-
lularly, whereas no D3-FITC is present in any activated
astrocyte surrounding the plaque. This indicates that
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Fig. 6. Four series of photomicrographs of coronal sections through the dorsal midline cortex and hippocampus of the D3-FITC infused
APP/PS1 mice: A1) unstained section of a blood vessel, note the labeled perivascular macrophages; A2) the same section stained with Congo
red showing A deposition; A3) combined image; B1) unstained section of midline cortex, showing D3-FITC labeling; B2) the same section
stained with Congo red showing A deposition; B3) combined image showing D3-FITC surrounding plaque cores; C1) unstained section of
area CA1; C2) the same section double stained with Congo red showing A deposition; C3) combined image showing D3-FITC in labeled
dystrophic neurites (blue arrow); D1) unstained section of stratum radiatum of area CA1; D2) the same section stained red for Iba-1 showing
microglial cells; and D3) combined image, note the three microglial cells that have taken up D3-FITC (red arrows).
microglial cells do contribute to the reduced A load
in the treated mice.
In the D3-FITC infused mice, however, compared
to the control infused mice, the dense A deposits
are associated with much lower numbers of acti-
vated microglia or activated astrocytes. This suggests
that the binding of D3-FITC to deposited A42
changes the structure of A42 evoking less inflam-
matory responses. Furthermore, the size of the A
deposits in the hippocampus is smaller in the D3-FITC
treated mice. Together, this suggests that the A in
the plaques, upon binding to D3-FITC, has changed
aggregation kinetics, for instance more amorphous
(non-depositing) A aggregates could be formed.
Finally, it should be noted that the number of deposits
that stain for thioflavine-S or Congo red has also been
significantly reduced in the hippocampus. This indi-
cates that either less new deposits were formed during
the four weeks of treatment or deposits were removed
by microglia. It is not likely that microglial cells have
taken up all A42-D3-FITC, since little intracellular
fluorescence is observed in most microglial cells. On
the other hand, clear FITC-fluorescence is present in
pericytes/perivascular macrophages [53, 54] indicat-
ing that these cells have taken up the D3-FITC-A42
complex. These cells may have increased the clearance
of the complex from the brain through the blood-
brain barrier [44, 53, 54]. In our earlier studies, we
have not observed uptake of D3-FITC in microglial
cells, indicating that the properties of the microglial
cells in these older animals are slightly different, most
likely due to the increased age of these mice [55, 56].
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Furthermore, we observed uptake of D3-FITC by neu-
rons near the infusion site, most likely by uptake of the
A42-D3-FITC complex.
It has been suggested that the progression of the
pathology in AD is related to the connections between
areas displaying early deposits and the cortical regions
showing later pathology, summarized by Hardy ([57])
in the “anatomical cascade hypothesis”. Our data
showing labeled neurons in layer II of the entorhinal
cortex that are most likely due to the retrograde trans-
port of D3-FITC (or the A42-D3-FITC complex),
confirm that A is retrogradely transported through
axons [30]. It should be noted that the neurons in the
entorhinal cortex showing intracellular D3-FITC are
healthy, and do not show signs of cell death. Further-
more, there is no increased inflammation in the area of
these intracellularly labeled neurons.
There was a significant improvement in the cogni-
tive deficits between the control and D3-FITC treated
mice in the Barnes maze task, but not in the water maze
task. The performance of the two groups of mice in the
water maze is quite similar to earlier reports [35, 58],
i.e., these Tg AD model mice are significantly impaired
in their water maze performance at 12 months of age,
and even more impaired at this age (22 months of age).
At the end of the first week of training, neither control
nor D3-FITC infused groups of animals have improved
their performance in the water maze. In contrast, at the
end of the second week of training (i.e., in the Barnes
maze), the D3-FITC groups of animals have slightly,
but significantly, improved their performance whereas
the control mice have not improved their performance.
This, most likely, is related to the very large decrease
in A load and plaque number in the hippocampus
of the treated group of mice compared to the con-
trol group. Finally, the data suggest that no cognitive
improvement is present after 6 12 weeks of treatment
(i.e., water maze testing), but that after 7 12 weeks of
treatment, a slight improvement is present. Together,
the data indicate that either a longer treatment or a
higher dose treatment in Tg AD model mice at this age
with D3 or D3-FITC likely might be more beneficial.
This is supported by the observation that plaque reduc-
tion was dependent on the distance from the infusion
site, suggesting that the amount of D3-FITC that was
infused was a limiting factor. This clearly raises the
possibility that the binding of D3-FITC to oligomeric
A42 significantly reduces synaptic pathology slowly,
leading to a slow increase in cognitive abilities. D3-
FITC diffused or was transported throughout the brain,
as suggested by the observed FITC-labeling of all
dense plaques. Dependent of the distance from the
infusion site, D3-FITC exerted different effects on the
A load. It significantly reduced soluble and insoluble
A species, even in the contralateral brain hemisphere
(Fig. 4). Dissolution of pre-existing plaques, however,
was observed predominantly near the injection site.
This suggests that higher D3-FITC concentrations, as
can be expected close to the injection site, are required
to dissolve pre-existing plaques during the treatment
period of 8 weeks. Lower D3-FITC concentrations are
still able to reduce soluble and insoluble A species
throughout the brain. Because the plaque load reduc-
tion is restricted to the small area around the infusion
site, the observed improvement of the cognitive behav-
ior may be attributed much more to the reduction of
soluble and insoluble A species than to any plaque
dissolution. But because plaques are a reservoir for
A species, their disappearance may still be a valu-
able long term objective in any treatment. Treatment
with D3 at higher concentrations and/or longer periods
may well be suitable to achieve enhanced plaque clear-
ance and even further reduced soluble and insoluble A
species.
This is a very important observation, because so
far, most animal trials were designed to treat the Tg
AD model animals at early stages, mostly before the
appearance of deficits in cognitive behavior [12, 59].
Such trials might therefore be named more correctly
prevention trials. This is currently heavily discussed as
a major reason why substances that had been shown to
be effective in such animal trials, later failed in clinical
trials, which have yet been done with patients clearly
diagnosed with AD, thus being at progressed stages
of the disease. Thus, after we had previously shown
that D3 is efficient for treatment of young Tg AD mice
by direct brain injection and oral application [26, 28],
it was the main purpose of the present study to treat
aged animals at progressed stages of pathology, when
cognitive deficits had been present already for quite a
while.
The data demonstrate that infusion with D3-FITC
leads to a reduction in the density of A deposits
in the hippocampus, whereas the infusion with the
vehicle solution does not. Cognitive deficits are not
significantly different between control and D3-FITC
infused mice in the water maze test, but the D3-FITC
infused mice do show a significant improvement on
the last day of cognitive testing. Furthermore, the
D3-FITC infused mice have a significant reduction
in the number of plaques in the hippocampus, and
in the amount of activated astrocytes and microglial
cells surrounding A plaques compared to the con-
trol infused mice. Together, this demonstrates that this
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peptide has great potential as a future treatment in
AD.
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